External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<p>We expect revenue and PAT CAGR of 13.3% and 12.3% respectively over the period FY21-FY23E and recommend BUY with TP of Rs 760.</p><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

We expect revenue and PAT CAGR of 13.3% and 12.3% respectively over the period FY21-FY23E and recommend BUY with TP of Rs 760.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Aarti Drugs: Low Demand, High RM Prices Impact Profitability; Capex to Drive Growth

Aarti Drugs Ltd

Aarti Drugs: Low Demand, High RM Prices Impact Profitability; Capex to Drive Growth